No profile data available.
Cnbx Pharmaceuticals Inc. (CNBX) is a healthcare company in the additional cancer treatment drugs industry, based in Bethesda, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$313,976. In Q2 2026 (the quarter ended February 28, 2026) revenue was $0. Its market capitalization was $160,576 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended August 31, 2025; market data as of October 9, 2026.
, a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome.
Cnbx Pharmaceuticals reported $0 in revenue for fiscal year 2025, down 100.0% from $130,074 in fiscal year 2024. In Q2 2026 revenue was $0.
$160,576 as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Marijuana Inc. (MAJI), Ocean Biomedical, Inc. (OCEA), Regen BioPharma, Inc. (RGBP), Medicus Pharma Ltd. (MDCX).